The mismatch between the body’s internal clock and our daily schedules not only make us sleepy, but it also contributes to the growing tide of obesity….
Read More »Obesity Projected to Grow to 42% in U.S.
Obesity in the US is projected to continue its rise over the next 18 years, extending to 42% of Americans by 2030, and the cost is projected to reach $549.5 billion….
Read More »How Red Wine Can Fight Obesity
A resveratrol-like compound found in red wine and fruits could have potential for fighting obesity by blocking fat uptake….
Read More »Simply Suppressing Hedonism or Truly a Magic Bullet for Obesity?
Aaron I. Vinik, MD, PhD, FCP, MACP Eastern Virginia Medical School, Strelitz Diabetes and Neuroendocrine Center Department of Medicine, Division of Endocrinology and Metabolism Norfolk, Virginia USA Topiramate is a structurally novel anti-epileptic drug effective in management of various types of epilepsy and prevention of migraine headaches. A sulfamate substituted …
Read More »Walking Switches Off ‘Obesity Genes’ and TV-Watching Ramps Them Up
Walking briskly for an hour every day can cut the effect of genetic tendencies toward obesity in half….
Read More »FDA Advisors Recommend Approval of Obesity Drug Qnexa
The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted overwhelmingly (20 to 2) in favor of approving the obesity drug Qnexa (Vivus, Inc.), a combination of phentermine and controlled-release topiramate. Qnexa could be the first prescription drug for obesity to reach the market since 1999.…
Read More »Qnexa Approval Paves Way for another Obesity Drug
An FDA advisory committee’s endorsement of the anti-obesity drug Qnexa could re-energize the pharmaceutical industry after several years of disappointment in trying to develop anti-obesity drugs.…
Read More »Protein’s Role In Obesity, Diabetes and Aging
Researchers at Washington University School of Medicine in St. Louis have identified a potent regulator of sensitivity to insulin….
Read More »Obesity Drug to Get Broader Label
Vivus Inc said the FDA has asked the company to remove a contraindication in the proposed label of its obesity drug Qnexa, a move that could help it reach a broader patient population.…
Read More »Obesity Diagnosis May Depend on Medical Professionals Weight
The study findings indicate that medical professionals with normal BMI more frequently reported discussing weight loss with patients than overweight or obese medical professionals….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.